Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Sanchez Arago M ^a   Formentini, L ^a   Martinez Reyes I ^a   Garcia Bermudez J ^a   Santacatterina, F ^a   Sanchez Cenizo L ^a   Willers, I M ^a   Aldea, M ^a   Najera L ^b   Juarranz A ^a   Lopez E C ^a   Clofent, J ^c   Navarro, C ^c   Espinosa, E ^d   Cuezva, J M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^c UNIVERSITY OF VIGO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

ATPase inhibitory factor 1; Cancer prognosis; Energy metabolism; H+ ATP synthase; Mitochondria; ROS signaling

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITORY FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENESIS; CARCINOMA; CELL DEATH; COLON CARCINOMA; ENDOMETRIUM; ENERGY METABOLISM; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; KIDNEY; LUNG CARCINOMA; MITOCHONDRION; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REGULATORY MECHANISM; STOMACH; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84880560280     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.9     Document Type: Article

References (67)

1. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M. The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta 2009; 1792: 1145-1158.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
3. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
5. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
6. Almeida A, Bolanos JP, Moncada S. E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation. Proc Natl Acad Sci USA 2010; 107: 738-741.
7. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339.
8. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
9. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-329.
10. Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010; 31: 567-576.
11. Boyer PD. The ATP synthase. A splendid molecular machine. Annu Rev Biochem 1997; 66: 717-749.
12. Matsuyama S, Xu Q, Velours J, Reed JC. The mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell 1998; 1: 327-336.
13. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006; 27: 925-935.
14. Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem 2000; 275: 7087-7094.
15. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y et al. Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 2006; 98: 1462-1473.
16. Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B, Steinberg P et al. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 2006; 281: 977-981.
17. D'Errico I, Salvatore L, Murzilli S, Lo Sasso G, Latorre D, Martelli N et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci USA 2011; 108: 6603-6608.
18. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci USA 2009; 106: 7131-7136.
19. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62: 6674-6681.
20. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007; 67: 9013-9017.
21. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65: 3162-3170.
22. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-Dglucose treatment. Mol Cancer Ther 2009; 8: 1916-1923.
23. Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, Gong FJ et al. Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol 2010; 7: 1506-1514.
24. Sanchez-Arago M, Cuezva JM. The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 2011; 9: 19.
25. de Heredia ML, Izquierdo JM, Cuezva JM. A conserved mechanism for controlling the translation of beta-F1-ATPase mRNA between the fetal liver and cancer cells. J Biol Chem 2000; 275: 7430-7437.
26. Willers IM, Isidoro A, Ortega AD, Fernandez PL, Cuezva JM. Selective inhibition of beta-F1-ATPase mRNA translation in human tumours. Biochem J 2010; 426: 319-326.
27. Ortega AD, Willers IM, Sala S, Cuezva JM. Human G3BP1 interacts with beta-F1- ATPase mRNA and inhibits its translation. J Cell Sci 2010; 123: 2685-2696.
28. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, Sanchez-Arago M et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 2010; 285: 25308-25313.
29. Formentini L, Sánchez-Aragó M, Sánchez-Cenizo L, Cuezva JM. The mitochondrial ATPase Inhibitory Factor 1 (IF1) triggers a ROS-mediated retrograde pro-survival and proliferative response. Mol Cell 2012; 45: 731-742.
30. Huang LJ, Chuang IC, Dong HP, Yang RC. Hypoxia-inducible factor 1alpha regulates the expression of the mitochondrial ATPase inhibitor protein (IF1) in rat liver. Shock 2011; 36: 90-96.
31. Shen L, Zhi L, Hu W, Wu MX. IEX-1 targets mitochondrial F1Fo-ATPase inhibitor for degradation. Cell Death Differ 2009; 16: 603-612.
32. Koppen M, Langer T. Protein degradation within mitochondria: versatile activities of AAA proteases and other peptidases. Crit Rev Biochem Mol Biol 2007; 42: 221-242.
33. Formentini L, Martinez-Reyes I, Cuezva JM. The mitochondrial bioenergetic capacity of carcinomas. IUBMB Life 2010; 62: 554-560.
34. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276: 4588-4596.
35. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26: 2095-2104.
36. Ortega AD, Sala S, Espinosa E, Gonzalez-Baron M, Cuezva JM. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNAbinding protein predicts a higher risk of disease recurrence. Carcinogenesis 2008; 29: 2053-2061.
37. Aldea M, Clofent J, Nunez de Arenas C, Chamorro M, Velasco M, Berrendero JR et al. Reverse phase protein microarrays quantify and validate the bioenergetic signature as biomarker in colorectal cancer. Cancer Lett 2011; 311: 210-218.
38. Cabezon E, Montgomery MG, Leslie AG, Walker JE. The structure of bovine F1-ATPase in complex with its regulatory protein IF1. Nat Struct Biol 2003; 10: 744-750.
39. Ichikawa N, Nakabayashi K, Hashimoto T. A yeast mitochondrial ATPase inhibitor interacts with three proteins that are easy to dissociate from the mitochondrial inner membrane. J Biochem 2002; 132: 649-654.
40. Lopez-Mediavilla C, Vigny H, Godinot C. Docking the mitochondrial inhibitor protein IF1 to a membrane receptor different from the F1-ATPase beta subunit. Eur J Biochem 1993; 215: 487-496.
41. Grisolía S, Hernandez-Yago J, Knecht E. Regulation of mitochondrial protein concentration: a plausible model which may permit assessing protein turnover. Curr Top Cell Regul 1985; 27: 387-396.
42. Izquierdo JM, Cuezva JM. Control of the translational efficiency of beta-F1-ATPase mRNA depends on the regulation of a protein that binds the 3' untranslated region of the mRNA. Mol Cell Biol 1997; 17: 5255-5268.
43. Willers IM, Martínez-Reyes I, Martínez-Diez M, Cuezva J. miR-127-5p targets the 3'UTR of human β-F1-ATPase mRNA and inhibits its translation. Biochim Biophys Acta-Bioenergetics 2012; 1817: 838-848.
44. Han L, Geng L, Liu X, Shi H, He W, Wu MX. Clinical significance of IEX-1 expression in ovarian carcinoma. Ultrastruct Pathol 2011; 35: 260-266.
45. Sasada T, Azuma K, Hirai T, Hashida H, Kanai M, Yanagawa T et al. Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer. Ann Surg Oncol 2008; 15: 609-617.
46. Bakala H, Delaval E, Hamelin M, Bismuth J, Borot-Laloi C, Corman B et al. Changes in rat liver mitochondria with aging. Lon protease-like reactivity and N(epsilon)-carboxymethyllysine accumulation in the matrix. Eur J Biochem 2003; 270: 2295-2302.
47. Stanyer L, Jorgensen W, Hori O, Clark JB, Heales SJ. Inactivation of brain mitochondrial Lon protease by peroxynitrite precedes electron transport chain dysfunction. Neurochem Int 2008; 53: 95-101.
48. Flynn JM, Neher SB, Kim YI, Sauer RT, Baker TA. Proteomic discovery of cellular substrates of the ClpXP protease reveals five classes of ClpX-recognition signals. Mol Cell 2003; 11: 671-683.
49. Mootha VK, Bunkenborg J, Olsen JV, Hjerrild M, Wisniewski JR, Stahl E et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003; 115: 629-640.
50. Butow RA, Avadhani NG. Mitochondrial signaling: the retrograde response. Mol Cell 2004; 14: 1-15.
51. Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci 2010; 35: 505-513.
52. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011; 194: 7-15.
53. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
54. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011; 21: 103-115.
55. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-107.
56. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320: 661-664.
57. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-8793.
58. Sanchez-Arago M, Formentini L, Garcia-Bermudez J, Cuezva JM. IF1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. Cell Cycle 2012; 11: 2963-2964.
59. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011; 17: 1627-1635.
60. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009; 114: 457-464.
61. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini I et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncology 2011; 12: 273-285.
62. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
63. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646.
64. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004; 378: 17-20.
65. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45: 365-373.
66. Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL et al. Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol 2009; 2: 138-145.
67. Martinez-Reyes I, Sanchez-Arago M, Cuezva JM. AMPK and GCN2-ATF4 signal the repression of mitochondria in colon cancer cells. Biochem J 2012; 444: 249-259. Enfermedades Raras